Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer

ClinicalTrials.gov ID: NCT02132949

Public ClinicalTrials.gov record NCT02132949. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 13, 2026, 4:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Multinational, Phase II Study to Evaluate Perjeta in Combination With Herceptin and Standard Neoadjuvant Anthracycline-Based Chemotherapy in Patients With HER2-Positive, Locally Advanced, Inflammatory, or Early-Stage Breast Cancer

Study identification

NCT ID
NCT02132949
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
401 participants

Conditions and interventions

Conditions

Interventions

  • 5-Fluorouracil Drug
  • Cyclophosphamide Drug
  • Docetaxel Drug
  • Doxorubicin Drug
  • Epirubicin Drug
  • Paclitaxel Drug
  • Pertuzumab Drug
  • Trastuzumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 13, 2014
Primary completion
Mar 2, 2016
Completion
Aug 24, 2020
Last update posted
Sep 16, 2021

2014 – 2020

United States locations

U.S. sites
24
U.S. states
16
U.S. cities
22
Facility City State ZIP Site status
University of South Alabama; Mitchell Cancer Institute Mobile Alabama 36604
Marin Specialty Care Greenbrae California 94904
California Pacific Medical Center San Francisco California 94115
MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center) Washington D.C. District of Columbia 20007
Washington Cancer Institute at MedStar Washington Hospital Center. Washington D.C. District of Columbia 20010
Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy) Jacksonville Florida 32256
Northwest Georgia Oncology Centers PC - Marietta Marietta Georgia 30060
Berkshire Medical Center Pittsfield Massachusetts 01201
Allina Health, Virginia Piper Cancer Institute Minneapolis Minnesota 55407
Saint Lukes Hospital Cancer Institute Kansas City Missouri 64111
Hackensack University Medical Center Hackensack New Jersey 07601
Regional Cancer Care Associates LLC - Morristown Morristown New Jersey 07962
San Juan Oncology Associates Farmington New Mexico 87401
MSKCC @ Commack Commack New York 11725
MSKCC @ West Harrison Harrison New York 10604
Mount Sinai Beth Israel Comprehensive Cancer Center New York New York 10011
Memorial Sloan Kettering Cancer Center New York New York 10065
MSKC @ Rockville Rockville Centre New York 11570
Mercy Clinic Oklahoma Communties, Inc Oklahoma City Oklahoma 73120
Harrington Cancer Center Amarillo Texas 79106
University of Utah; Huntsman Cancer Hospital Salt Lake City Utah 84112
Blue Ridge Cancer Care Roanoke Virginia 24014
PeaceHealth St. Joseph Cancer Center Bellingham Washington 98225
Northwest Medical Specialties Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 56 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02132949, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 16, 2021 · Synced May 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02132949 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →